Stoke Therapeutics Management
Management criteria checks 4/4
Stoke Therapeutics' CEO is Ed Kaye, appointed in Oct 2017, has a tenure of 7.08 years. total yearly compensation is $3.53M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 0.051% of the company’s shares, worth $308.64K. The average tenure of the management team and the board of directors is 3.8 years and 6.2 years respectively.
Key information
Ed Kaye
Chief executive officer
US$3.5m
Total compensation
| CEO salary percentage | 17.7% |
| CEO tenure | 7.1yrs |
| CEO ownership | 0.05% |
| Management average tenure | 3.8yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Nov 08
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Nov 06Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
Compensation vs Market: Ed's total compensation ($USD3.53M) is about average for companies of similar size in the US market ($USD3.17M).
Compensation vs Earnings: Ed's compensation has been consistent with company performance over the past year.
CEO
Ed Kaye (75 yo)
7.1yrs
Tenure
US$3,533,210
Compensation
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.1yrs | US$3.53m | 0.051% $ 308.6k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.76% $ 4.6m | |
| Chief Medical Officer | 7.1yrs | US$1.65m | 0.0047% $ 28.4k | |
| Co-Founder & Senior VP of Discovery Research | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Corporate Secretary & General Counsel | 3.8yrs | no data | 0.0049% $ 29.7k | |
| Chief Communications Officer | 3.8yrs | no data | no data | |
| Chief Human Resources Officer | 5.1yrs | no data | no data | |
| Senior VP of Quality & Chief Regulatory Affairs Officer | 5.9yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Management: STOK's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.1yrs | US$3.53m | 0.051% $ 308.6k | |
| Co-Founder & Independent Director | 10.4yrs | US$198.33k | 0.76% $ 4.6m | |
| Independent Director | 9.3yrs | US$237.33k | 3.54% $ 21.4m | |
| Independent Director | 9.2yrs | US$198.33k | 0.034% $ 205.5k | |
| Independent Director | 1.2yrs | US$394.03k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$209.33k | 0% $ 0 | |
| Independent Chairman | 6.2yrs | US$211.83k | 0.060% $ 362.8k |
6.2yrs
Average Tenure
61yo
Average Age
Experienced Board: STOK's board of directors are considered experienced (6.2 years average tenure).